These findings suggest that HBx promotes hepatocarcinogenesis by inducing RBM15-dependent cFAM210A degradation, while cFAM210A itself represents a potential therapeutic target for HBV-related HCC (Yu et al., 2023). The gene discussed is RBM15; the disease is hepatocellular carcinoma.